During the Association for Accessible Medicines’ Access! 2019 meeting, Doug Long, vice president of industry relations at IQVIA, gave an update about what trends are being identified in the generic and biosimilars markets across the globe.
During the Association for Accessible Medicines’ Access! 2019 meeting, Doug Long, vice president of industry relations at IQVIA, gave an update about what trends are being identified in the generic and biosimilars markets across the globe.
According to data collected by IQVIA, FDA abbreviated New Drug Applications (ANDA) are being approved at twice the typical rate for the fourth year in a row. According to Long, however, the ANDA backlog is estimated to be around 50% of peak level (nearly 4000) and getting that number down to zero is somewhat unlikely.
Interestingly, though the FDA has been approving ANDAs at an accelerated rate since 2014, the number of ANDA withdrawals has also increased. In 2018, the FDA approved a record number of 735 ANDAs, and the agency also saw a record 71 withdrawals. Furthermore, many ANDA products, once approved, are not being launched. Of the 735 that were approved in 2018, as of December 2018, only 261 had launched.
Long explained that in 2017, spending on medicines in the United States grew 0.6%, notably slower than in years past. Additionally, Long stated that in 2017, there was a 44% difference in the average wholesale acquisition cost (WAC) to net discount for branded protects and a 64% difference for generics. “The most meaningless data point that I’ve ever come across is list pharmaceutical prices,” said Long.
He then moved on to discuss the trends seen in the biosimilar market, both locally and abroad. Long presented data that showed the United States to be among the slowest developed countries to commercialize when the first biosimilar of a molecule becomes available.
“For example, biosimilar [adalimumab] (Humira) launched in Europe in October 2018. We’re not expecting that here [in the United States] until 2023, unless Boehringer Ingelheim figures out their litigation” against the reference product developer, AbbVie.
In terms of market share, Long broke down the data by product per molecule as of January 2019:
Filgrastim:
Infliximab:
Pegfilgrastim:
Long believes that the lack of biosimilar uptake in the United States “is not a regulatory problem, it’s commercial.” In countries where hospitals or providers are required to prescribe their patient the lowest-cost available option, such as Denmark, biosimilar penetration (as of October 2018) was extremely high. For biosimilar infliximab alone, Denmark reported figures of 98.5% market penetration.
However, the biosimilar market in the United States still holds great potential, he said. From 2019 to 2023, the impact of brand loss of exclusivity is estimated to be worth nearly $95 billion, opening up the market for new biosimilar entry.
Long quoted an industry consultant he questioned about what he sees lies in store for the biosimilar market. He said, “As more and more products come to market, and the products are in wider distribution and there are no identified problems, then perhaps the uptake in the market may improve.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
June 24th 2024Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
June 24th 2024Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination therapy utilizing a pegfilgrastim biosimilar in patients with advanced hepatocellular carcinoma.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
2 Commerce Drive
Cranbury, NJ 08512